scPharmaceuticals Inc. SCPH
Set alert
At close · Oct 7
52-week range unavailable
- YTD
- +60.17%
- 1 year
- +32.48%
- Open
- 5.67
- Prev close
- 5.67
- Mkt cap
- 171.14M
- Vol
- 10.90M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.67
- High
- 5.67
- Forward P/E
- -4.68
- Beta
- 0.00
- Short ratio
- 11.41
- Inst. own
- 81.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 3.82
- 200-d avg
- 4.45
- 1y target
- 17.50
Key statistics
- Market cap
- 171.14M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- -4.68
- PEG ratio
- 0.00
- Price / sales
- 5.65
- Price / book
- 3.30
- EPS (TTM)
- -1.95
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -264.60%
- Revenue (TTM)
- 30.28M
- Revenue growth
- 164.10%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 50.04M
- Short % of float
- 12.90%
- 50-day average
- 3.82
- 200-day average
- 4.45
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 17.50
- Target (high)
- 25.00
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.38667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.30 | -0.37 | -0.07 | -23.33% |
| Aug 14, 2024 | Jun 1, 2024 | -0.44 | -0.44 | 0.00 | 0.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.44 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.45 | -0.36 | +0.09 | +20.00% |
| May 14, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.42 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | Craig-Hallum | main | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 7, 2023 | Craig-Hallum | init | — | Buy |
About scPharmaceuticals Inc.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- scpharmaceuticals.com
News
- SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
- SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
- SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
- Shareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public Shareholders
- MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
- scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
- scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
- scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
- scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
Your note
Sign in to keep a note on SCPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| NOKES RACHAEL | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 5, 2024 | 72,851 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 12, 2024 | 0 |
| SCHAEFFER LEONARD DAVID | Director | Conversion of Exercise of derivative security | Aug 25, 2024 | 54,451 |
| TUCKER JOHN H JR | Chief Executive Officer | Stock Award(Grant) | Jan 17, 2024 | 254,207 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 12.11% | 6,059,528 | 20.72M | Sep 29, 2024 |
| Rubric Capital Management LP | 9.54% | 4,775,000 | 16.33M | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.24% | 4,124,367 | 14.11M | Sep 29, 2024 |
| King Luther Capital Management | 4.45% | 2,225,790 | 7.61M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 4.09% | 2,049,009 | 7.01M | Sep 29, 2024 |
| Blackrock Inc. | 3.70% | 1,853,749 | 6.34M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.28% | 1,138,835 | 3.89M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.39% | 695,542 | 2.38M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.61% | 305,088 | 1.04M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.58% | 291,917 | 998.36K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.53% | 265,235 | 907.10K | Oct 30, 2024 |
| Thrivent Small Cap Growth Fund | 0.36% | 178,614 | 610.86K | Jul 30, 2024 |